KENILWORTH, N.J. A growth and diversification strategy that started in 2003 has produced good performance at Schering-Plough, the drug maker announced Monday.
The company reported strong sales growth, including sales in other countries, as well as a strong phase III pipeline, which the company called the strongest in its history. The company reported net income available for common shareholders of $398 million for the second quarter of this year.
“We are very pleased to see another quarter of strong performance and broad-based growth for our company,” chairman and chief executive officer Fred Hassan said.
GAAP net sales for the 2008 second quarter totaled $4.9 billion, up 55 percent as compared with the second quarter of 2007.